Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more
Open Access

Clinical utility of RAS mutations in thyroid cancer: a blurred picture now emerging clearer

BMC Medicine201614:12

https://doi.org/10.1186/s12916-016-0559-9

Received: 18 January 2016

Accepted: 18 January 2016

Published: 27 January 2016

Abstract

RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer—RAS mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on molecular-based practice in the management of thyroid cancer.

Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/s12916-015-0419-z

Keywords

RAS mutationThyroid noduleThyroid cancerMolecular markerDiagnosisPrognosis

Background

The RAS oncogene plays a fundamental role in human tumorigenesis [1]. Activating mutations in its three proto-oncogenes—HRAS, KRAS and NRAS—are found in nearly all human cancers. Thyroid cancer is one of the earliest cases where activating RAS mutations were discovered [2]. Today, the role of RAS oncogene in thyroid tumorigenesis has been well established [35]. Mutations in RAS genes occur, on average, in 30–45 % follicular thyroid cancer (FTC), 30–45 % follicular variant papillary thyroid cancer (FVPTC), 20–40 % poorly differentiated thyroid cancer (PDTC), 10–20 % anaplastic thyroid cancer, and rarely classical papillary thyroid cancer (PTC). RAS mutations also occur in 20–25 % benign follicular thyroid adenoma (FTA). Considerable interest has been drawn to the potential clinical utility of RAS mutations as diagnostic and prognostic molecular markers, among other molecular markers, for thyroid cancer [6]. Given these occurrence patterns in thyroid tumors, however, RAS mutations themselves have low diagnostic sensitivities and specificities. Also, the role of RAS mutations in the clinical behavior of thyroid tumor is uncertain. Consequently, the clinical picture of RAS mutations in thyroid cancer has been a blurred one.

RAS mutations as diagnostic molecular markers for thyroid nodules

Clinical management of thyroid cancer usually starts with the evaluation of thyroid nodules, which is extremely common, with a prevalence of 50–70 % on ultrasonography [7, 8]. The diagnostic mainstay of thyroid nodules is fine needle aspiration biopsy (FNAB). In the last decade, much effort has been made to apply RAS mutations as diagnostic molecular markers to FNAB of thyroid nodules, particularly those with indeterminate cytology, which currently represents a major diagnostic challenge in clinical practice. Indeterminate thyroid cytology includes three categories—atypia of undetermined significance (AUS), follicular neoplasm (FN) and suspicious for malignancy [9]. Surgical treatment for thyroid nodules cytologically suspicious for malignancy is generally accepted because of its high preoperative malignancy probability (around 60–70 %) and the treatment decision seems to be relatively easy to make. How to treat AUS and FN, which have a moderate risk of malignancy (10–30 %), is a more challenging dilemma in treatment decision making. Resolution of this dilemma is believed to rely on the development of effective diagnostic molecular marker-based tests [6]. An ideal diagnostic molecular marker should have a 100 % or near-100 % sensitivity and specificity. Yet, RAS mutations have been proven to have inferior sensitivities and specificities for thyroid cancer. An effective strategy to apply RAS mutations to the diagnosis of thyroid cancer is their combinational use with other molecular markers, particularly genetic markers [6]. A prominent example is the panel of genetic makers, including RAS mutations, BRAF V600E mutation, RET/PTC and PAX8/PPARγ rearrangements, which, in a single-center unblinded study, yielded increased diagnostic sensitivities for thyroid cancer in the indeterminate cytological setting to 88 % for AUS and 87 % for FN [10]. The sensitivity of this test on overall non-selected thyroid cytology was still high at 80 %, albeit lower, in a double-blinded multicenter study [11]. The recently discovered TERT promoter mutations [12] were shown to be diagnostically applicable to FNAB [13]. Expansion of the genetic diagnostic panel to include additional genetic markers, including TERT promoter mutations, has resulted in an improved sensitivity for the FN category to 90 %, bringing the negative predictive value to 96 % [14]. Indeterminate thyroid cytology consists mostly of follicular thyroid tumors and the malignant types are mainly FTC and FVPTC, which most commonly harbor RAS mutations. Therefore, RAS mutations are an important component that helps make the genetic panel diagnostically sensitive, propelling for high negative predictive values. It is expected that as the diagnostic efficiency of the genetic panel containing RAS mutations is confirmed and further improved, ideally through large blinded multicenter optimizing studies, it will become possible to use such a genetic panel to help reliably rule out malignancy for thyroid nodules.

RAS mutations in cytologically benign thyroid nodules

Since FTA is a main thyroid tumor in the indeterminate cytology category and RAS mutations occur commonly in FTA, albeit less frequently than FTC and FVPTC, use of the diagnostic genetic panel is expected to result in a large number of RAS mutation-positive but cytologically benign or indeterminate thyroid nodules. How to appropriately manage these nodules has been unclear. Because of the preferential occurrence of RAS mutations in malignant over benign thyroid tumors and the established oncogenic functions of RAS mutations in human tumorigenesis, there is reasonable concern about the prognosis of cytologically benign or indeterminate thyroid nodules harboring RAS mutations. Consequently, some physicians may recommend surgical treatment for all RAS mutation-positive thyroid nodules. Others, on the other hand, may argue for non-surgical management and conservative follow-up for RAS mutation-positive but cytologically benign thyroid nodules, since non-surgical management of cytologically benign thyroid nodules is currently the standard management [15]. This confusion is a result of the lack of knowledge of the clinical behavior of such nodules in the long run.

The picture now becomes clearer with light shed by a marvelous recent study from Medici et al. of the Alexander group [16]. In this study, the authors investigated the diagnostic value of RAS mutations on FNAB for thyroid cancer and the clinical behavior of RAS mutation-positive thyroid tumors. As expected, the authors confirmed the low diagnostic sensitivity and specificity of RAS mutations when used alone. An important novel finding, however, is that a group of RAS mutation-positive but cytologically benign thyroid nodules that were available for non-surgical management and conservative monitoring all showed excellent stability without radiographic growth or adverse clinical consequences after a long-term clinical follow-up (mean 8.3 years). This provides the first evidence that RAS mutation-positive but cytologically benign thyroid nodules behave as true benign nodules and can be conservatively managed for long term. Given the expected rising number of such patients in the coming years, long-term non-surgical management of such nodules would likely have many benefits, such as cost savings, avoidance of potential surgical complications and preservation of the thyroid function. It should be noted, though, that the prognosis of RAS-positive but cytologically benign thyroid nodules in an even longer term beyond the follow-up time in the Medici et al. study remains unknown. Further studies with longer follow-up durations are needed to provide an even clearer picture. Also, the clinical significance of RAS mutations in AUS/FN nodules remains unclear.

Benign clinical prognosis of benign thyroid nodules

Consistent with the limited role of RAS mutations in benign thyroid nodules discussed above, a recent publication in BMC Medicine by Medici et al., demonstrated the safety of long-term conservative clinical follow-up of cytologically benign thyroid nodules [17]. It has not been established how long benign thyroid nodules can be safely and conservatively followed clinically. Repeat evaluation of benign thyroid nodules at 1–2 years or even shorter intervals is currently common practice. This practice, however, has no direct evidence to support. In 1,254 patients with 1,819 cytologically benign thyroid nodules, with a median time of 1.4 years to first follow-up (ranging 0.5–14.1 years), the authors found no difference in malignancy or mortality between various follow-up intervals. Even though after three years of follow-up, some benign thyroid nodules could grow and even cause compressive symptoms requiring thyroidectomy in certain cases, the authors did not identify a difference in risk of malignancy. The results support the authors’ recommendation that the interval of repeat evaluation can be safely extended to three years, reducing the unnecessary visits and medical interventions. This will likely have a profound impact on the healthcare saving, given the large number of patients with benign thyroid nodules. These findings by Medici et al. are consistent with a recent Italian study similarly showing a generally long-term stability and benign prognosis of benign thyroid nodules [18]. These clinical findings also again support the notion that RAS mutation alone plays a limited role in the transformation of benign thyroid nodules as many of such nodules expectedly harbor RAS mutations [4].

RAS mutations as prognostic molecular markers for thyroid cancer

Another important finding in the earlier Medici et al. study [16] is that, even when histologically confirmed to be malignant, the RAS mutation-positive tumors have limited aggressiveness; these are usually FVPTC without aggressive tumor behavior, such as extrathyroidal extension, lymph node metastasis and distant metastasis. These tumors are highly curable and have an excellent prognosis. This is in contrast to BRAF V600E mutation [1921] or TERT promoter mutations [12, 13, 22, 23], which are associated with aggressiveness and poor clinical outcomes of thyroid cancer. Medici et al. confirmed the association of the BRAF V600E mutation with aggressive behavior of thyroid cancer in their study [16]. These results are consistent with the previous findings that, compared with the BRAF V600E mutation, RAS mutations were associated with better differentiation of thyroid cancer as reflected by normal or near-normal expression of thyroid iodide-handling genes in contrast to the considerable down-regulation of these genes with BRAF mutation [4, 24, 25]. Some studies showed an association between poor tumor behavior and RAS mutations in FTC [26] and PDTC [27, 28]. This likely reflects the coexistence of RAS mutations with additional oncogenic alterations, such as TERT promoter mutations; RAS mutations and TERT promoter mutations are significantly associated with each other in thyroid cancer [29] and coexistence of the two types of mutations was shown to be associated with a significantly higher tumor recurrence compared with RAS mutation alone in FTC [30], similar to the coexistence of BRAF V600E mutation with TERT promoter mutations that is associated with sharply increased aggressive clinicopathological behavior, tumor recurrence and patient mortality in PTC [23, 31]. RAS mutation alone is most likely associated with limited aggressiveness of thyroid cancer. This concept is in fact supported by a mouse model in which Kras mutation alone caused only benign thyroid neoplasia and its coexistence with Pten deletion in the PI3K pathway caused transformation of the tumor into FTC with metastasis [32].

One advantage of the expanded diagnostic genetic panel is that it tests not only RAS mutations, but also other important oncogenic genetic changes, including TERT promoter mutations. Therefore, coexistence of RAS mutations with additional oncogenic changes can be identified using such a genetic panel; the result should then be treated differently than finding RAS mutation alone in terms of prognostic significance. If only RAS mutations are found in differentiated thyroid cancer, it is reasonable and safe to assume a good prognosis.

Conclusions

Studies in recent years together with the studies by Medici et al. [16, 17] have shed bright light on the role of RAS mutations in the clinical behavior of thyroid tumors and their value in assisting the management of thyroid nodules and thyroid cancer, making a previously blurred clinical picture now emerging clearer. Overall, cytologically benign thyroid nodules, even when harboring RAS mutations, have an excellent prognosis and can be safely and conservatively followed at relatively long time intervals; differentiated thyroid cancer, when harboring RAS mutations alone without other coexisting genetic alterations, generally lacks aggressive behaviors. Given this advancement in understanding RAS mutations, the following recommendations on their clinical use as diagnostic and prognostic molecular markers may be considered: 1) RAS mutations have an important diagnostic value as a component of a genetic marker panel that has high negative predictive values and can thus help diagnostically rule out thyroid malignancy; 2) RAS mutation-positive but cytologically benign thyroid nodules can be non-surgically managed and followed for long term; 3) RAS mutation-positive differentiated thyroid cancer has an excellent prognosis and can be treated with less aggressive measures, e.g. hemithyroidectomy, in the appropriate clinical settings; and 4) unless clinically indicated otherwise, RAS mutation-positive AUS or FN thyroid nodules may be treated with hemithyroidectomy and, if shown to be benign on additional molecular tests, such as gene expression classifier [33], may be considered to be non-surgically managed and conservatively followed. These uses of RAS mutations as molecular markers are applicable only when RAS mutation alone exists; if coexisting oncogenic genetic alterations are also found, such as TERT promoter mutations or mutations in the PI3K pathway, the tumor should be treated more aggressively in appropriate clinical settings.

Declarations

Acknowledgements

This work was supported by the US National Institutes of Health (NIH), with grants R01CA113507 and R01CA189224 to M Xing.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine

References

  1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Suárez HG, Du Villard JA, Caillou B, Schlumberger M, Tubiana M, Parmentier C, et al. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene. 1988;2:403–6.PubMedGoogle Scholar
  3. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20:697–706.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13:184–99.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist. 2013;18:926–32.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381:1058–69.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553–9.View ArticlePubMedGoogle Scholar
  8. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39:699–706.View ArticlePubMedGoogle Scholar
  9. Cibas ES, Ali SZ. NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009;132:658–65.View ArticlePubMedGoogle Scholar
  10. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1,056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390–7.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid. 2014;24:1479–87.View ArticlePubMedGoogle Scholar
  12. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20:603–10.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer. 2014;21:825–30.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627–34.View ArticlePubMedGoogle Scholar
  15. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.View ArticleGoogle Scholar
  16. Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, et al. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015;13:184.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Medici M, Liu X, Kwong N, Angell TE, Marqusee E, Kim MI, et al. Long-interval versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study. BMC Medicine. 2016; doi:10.1186/s12916-016-0554-1
  18. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, et al. The natural history of benign thyroid nodules. JAMA. 2015;313:926–35.View ArticlePubMedGoogle Scholar
  19. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.View ArticlePubMedGoogle Scholar
  20. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493–501.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33:42–50.View ArticlePubMedGoogle Scholar
  22. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185.View ArticlePubMedGoogle Scholar
  23. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32:2718–26.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–56.View ArticlePubMedGoogle Scholar
  25. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.View ArticleGoogle Scholar
  26. Fukahori M, Yoshida A, Hayashi H, Yoshihara M, Matsukuma S, Sakuma Y, et al. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort. Thyroid. 2012;22:683–9.View ArticlePubMedGoogle Scholar
  27. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. RAS mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226–35.View ArticlePubMedGoogle Scholar
  28. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735–41.View ArticlePubMedGoogle Scholar
  29. Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016 Jan 5. pii: ERC-15-0533. [Epub ahead of print]Google Scholar
  30. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol. 2015;399:288–95.View ArticlePubMedGoogle Scholar
  31. Xing M, Liu R, Bishop J. TERT promoter and BRAF mutations cooperatively promote papillary thyroid cancer-related mortality. Thyroid. 2014;24:A-131.View ArticleGoogle Scholar
  32. Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009;69:3689–94.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.View ArticlePubMedGoogle Scholar

Copyright

© Xing. 2016

Advertisement